期刊文献+

甲状腺微小乳头状癌发生及淋巴结转移的相关因素分析 被引量:5

下载PDF
导出
摘要 目的探讨CD56、Cyclin D1、C-met在甲状腺微小乳头状癌(papillary thyroid microcarcinoma,PTMC)和癌旁甲状腺组织中的表达及其与淋巴结转移的关系。方法应用免疫组化SP法检测59例PTMC中CD56、Cyclin D1和C-met蛋白表达,分析三者在PTMC中的表达与淋巴结转移的关系。结果癌旁甲状腺组织中CD56的表达显著高于PTMC组织(P<0.05);PTMC组织中Cyclin D1和C-met蛋白表达显著高于癌旁甲状腺组织(P<0.005),PTMC的淋巴结未转移组中Cyclin D1蛋白半定量评分高于转移组(P<0.05);等级相关分析显示Cyclin D1与C-met蛋白在PTMC中表达有相关性(r s=0.59,P<0.01)。结论 CD56、Cyclin D1、C-met蛋白均可影响PTMC的发生,Cyclin D1可作为其淋巴结转移的预测因子,与C-met联合检测对提示是否淋巴结转移具有重要意义。
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2013年第8期909-911,共3页 Chinese Journal of Clinical and Experimental Pathology
基金 吉林省发改委资助项目(2011220101000936)
  • 相关文献

参考文献9

二级参考文献60

  • 1滕晓东,王丽君,姚洪田,李君,丁伟,严丽萍.细胞角蛋白19、galectin-3、HBME-1在甲状腺病变上的表达及鉴别诊断意义[J].中华病理学杂志,2004,33(3):212-216. 被引量:33
  • 2郑璐滢,朱建善,王家东,许雁萍.Galectin-3、CK19和TPO表达在甲状腺良恶性肿瘤病理诊断中的价值[J].临床与实验病理学杂志,2005,21(4):449-453. 被引量:18
  • 3王晓红,刘雨飞,鲍宇浓,崔全才,王德田.甲状腺乳头状癌RET、CK19、TG、Ki-67的表达[J].临床与实验病理学杂志,2006,22(6):692-695. 被引量:14
  • 4Cunningham BA, Hemperly J J, Murray BA, et al. Neural cell adhesion molecule : structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing [ J ]. Science, 1987, 236(4803) :799-806.
  • 5Kontogianni K, Nicholson AG, Butcher D, et al. CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artifact [ J ]. J Clin Pathol, 2005, 58(9) :978-980.
  • 6Kwong YL, Chan AC, Liang R, et al. CD56 + NK lymphomas: clinicopathological features and prognosis [ J ]. Br J Haematol,1997,97(4) : 821-829.
  • 7Mann KP, DeCastro CM, Liu J, et al. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes [ J]. Am J Clin Pathol, 1997,107 (6) :6534560.
  • 8Scarpino S, Di Napoli A, Melotti F, et al, Papillary carcinoma of the thyroid : low expression of NCAM ( CD56 ) is associated with downregulation of VEGF-D production by tumour cells [ J ]. J Pathol, 2007, 212(4) :411-419.
  • 9EI Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid[J]. Dign Pathol, 2008, 3 : 5.
  • 10EI Demellawy D, Nasr AL, Babay S, et al. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid [J]. Pathol Res Pract, 2009,205(5) :303-309.

共引文献63

同被引文献27

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012[J]. CA Cancer J Clin, 2012,62(5):283-98.
  • 2Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors[J]. J Cancer Epidemiol, 2013,2013:965212.
  • 3Guan H, Ji M, Xing M, et al. Association of high iodine intake with the T1779A BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2009,94(5):1612-7.
  • 4Kim T H, Park Y J, Lim J A, et al. The association of the BRAF(V600E)mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer:a meta-analysis[J]. Cancer, 2012,118(7):1764-73.
  • 5Edge S B, Byrd D R, Carducci M A, et al. AJCC Cancer Staging Manual[M]. 7th ed. New York: Springer, 2009:87-96.
  • 6Shao J, Teraishi F, Katsuda K, et al. p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells[J]. Biochem Biophys Res Commun, 2002,290(3):1101-7.
  • 7Frasca F, Nucera C, Pellegriti C, et al. BRAF(V600E)mutateon and the biology of papillary thyroid cancer[J]. Endoer Rlat Cancer, 2008,15(1):191-205.
  • 8Nikiforov Y E, Nikiforova M N. Molecular genetics and diagnosis of thyoid cancer[J]. Nat Rev Endocrinol, 2011,7(10):569-80.
  • 9Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mutateon and p27 kip1 expression in papillary carcinomas of the thyroid ≤1cm and their paired lymph node metastases[J]. Cancer, 2007,110(6):1216-8.
  • 10Xing M. BRAF mutateon in thyroid cancer[J]. Endecr Relat Cancer, 2005,12(2):245-62.

引证文献5

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部